NVCR - NovoCure Limited

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
69.39
-1.63 (-2.30%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close71.02
Open71.68
Bid66.00 x 900
Ask69.32 x 800
Day's Range68.47 - 72.59
52 Week Range26.02 - 72.59
Volume865,044
Avg. Volume630,193
Market Cap6.645B
Beta (3Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-0.59
Earnings DateJul 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est61.83
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    CMS Establishes 2019 Monthly Fee Schedule Amount for Optune®

    Novocure (NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. The announcement by CMS follows an announcement earlier this morning by the durable medical equipment (DME) Medicare Administrative Contractors (MACs) that a final local coverage determination (LCD) providing coverage, effective September 1, 2019, of Optune for Medicare beneficiaries with newly diagnosed glioblastoma (GBM) has been established. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields.

  • NovoCure (NVCR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
    Zacks2 days ago

    NovoCure (NVCR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

    NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire2 days ago

    Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma

    Novocure (NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local coverage determination (LCD) providing coverage of Optune for Medicare beneficiaries with newly diagnosed glioblastoma (GBM) effective September 1, 2019. The final LCD and a summary response to comments are available in the U.S. Centers for Medicare & Medicaid Services (CMS) coverage database. “We are extremely pleased that CMS has established coverage of Optune for patients with newly diagnosed GBM and that many of the restrictions originally proposed were removed in response to public comment,” said Bill Doyle, Novocure’s Executive Chairman.

  • Novocure Stock Gave Quick Swing Trading Profit
    Investor's Business Daily15 days ago

    Novocure Stock Gave Quick Swing Trading Profit

    Capturing a powerful move in a short time is one of the main goals of swing trading. Novocure stock provides an example of a recent swing trade.

  • GuruFocus.com18 days ago

    Novocure Ltd (NVCR) CEO Asaf Danziger Sold $11.7 million of Shares

    CEO of Novocure Ltd (NASDAQ:NVCR) Asaf Danziger sold 187,500 shares of NVCR on 06/28/2019 at an average price of $62.15 a share.

  • Business Wire18 days ago

    Novocure to Report Second Quarter 2019 Financial Results

    Novocure announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended June 30, 2019, at 8 a.m.

  • 3 Cancer-Treatment Stocks to Buy
    Motley Fool21 days ago

    3 Cancer-Treatment Stocks to Buy

    These three businesses are a great way for investors to support the war on cancer.

  • NovoCure (NVCR) Jumps: Stock Rises 7.1%
    Zacks22 days ago

    NovoCure (NVCR) Jumps: Stock Rises 7.1%

    NovoCure (NVCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Business Wire24 days ago

    German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune’s Survival Benefit for Patients with Newly Diagnosed Glioblastoma

    Novocure (NVCR) today announced that the German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published its rapid report concluding that, based on a review of Novocure’s EF-14 phase 3 pivotal trial, patients with newly diagnosed glioblastoma (GBM) lived longer when treated with Optune in addition to standard chemotherapy, without affecting quality of life. This positive conclusion is an important step in Novocure’s process to secure national reimbursement for Optune in Germany.

  • What does NovoCure Limited's (NASDAQ:NVCR) Balance Sheet Tell Us About Its Future?
    Simply Wall St.26 days ago

    What does NovoCure Limited's (NASDAQ:NVCR) Balance Sheet Tell Us About Its Future?

    Mid-caps stocks, like NovoCure Limited (NASDAQ:NVCR) with a market capitalization of US$5.7b, aren’t the focus of most...

  • GuruFocus.comlast month

    Novocure Ltd (NVCR) CEO Asaf Danziger Sold $11.3 million of Shares

    CEO of Novocure Ltd (NASDAQ:NVCR) Asaf Danziger sold 190,338 shares of NVCR on 06/18/2019 at an average price of $59.37 a share.

  • TheStreet.comlast month

    Novocure Could Climb Even Further; Here's Where to Buy

    During the Lightning Round of "Mad Money" Monday, Jim Cramer had this to say about cancer cure company Novocure Ltd. : "I think this is fantastic." The charts of NVCR are pretty strong, so we want to be a buyer. In this daily bar chart of NVCR, below, we can see can see a clear pattern of higher lows and higher highs -- the simple definition of an uptrend.

  • Hedge Funds Have Never Been This Bullish On NovoCure Limited (NVCR)
    Insider Monkeylast month

    Hedge Funds Have Never Been This Bullish On NovoCure Limited (NVCR)

    Is NovoCure Limited (NASDAQ:NVCR) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. […]

  • Motley Foollast month

    Why NovoCure's Regulatory News Is a Huge Win for Investors

    The cancer-focused medical-device maker received the go-ahead to enter a brand-new market. Here's why the news should make investors giddy.

  • Is NovoCure Limited's (NASDAQ:NVCR) CEO Overpaid Relative To Its Peers?
    Simply Wall St.last month

    Is NovoCure Limited's (NASDAQ:NVCR) CEO Overpaid Relative To Its Peers?

    In 2002 Asaf Danziger was appointed CEO of NovoCure Limited (NASDAQ:NVCR). This report will, first, examine the CEO...

  • Motley Foollast month

    You Need This IPO On Your Radar

    Shockwave Medical's stock market debut got buried amid the recent surge of better-known offerings, but we’re digging this gem back out.

  • Why NovoCure Stock Jumped 20.5% in May
    Motley Foollast month

    Why NovoCure Stock Jumped 20.5% in May

    Shares of this medical device company that's aiming to revolutionize cancer treatment bucked last month's downtrend.

  • 3 Fast-Growing Healthcare Stocks to Buy If the Market Crashes
    Motley Fool2 months ago

    3 Fast-Growing Healthcare Stocks to Buy If the Market Crashes

    These top healthcare stocks could be worth adding to portfolios if the market sells off sharply.

  • Benzinga2 months ago

    The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...

  • Business Wire2 months ago

    Novocure to Participate in the Jefferies 2019 Global Healthcare Conference

    Novocure (NVCR) announced today that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City. Mr. Doyle will also participate in one-on-one meetings with investors throughout the day. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the events.

  • Business Wire2 months ago

    FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma

    Novocure (NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM). NovoTTF-100L is a non-invasive, antimitotic cancer treatment that delivers Tumor Treating Fields to the region of the tumor.

  • Motley Fool2 months ago

    Insulet and Novocure Are Going Gangbusters

    These two medical-device gems posted record results in the first quarter that send their stocks shooting higher.

  • Business Wire2 months ago

    Medicare Issues Proposed Local Coverage Determination that Provides Coverage of Optune® for Newly Diagnosed Glioblastoma

    Novocure (NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM). Proposed LCDs are subject to a 45-day public comment period during which the DME MACs will consider feedback from patients, advocacy groups, prescribers and the general public prior to finalizing the LCD. The coverage policy criteria proposed by the DME MACs is generally similar to Optune’s commercial coverage criteria for newly diagnosed glioblastoma (GBM) with the exception of a proposed restriction on beneficiary site of care.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of NVCR earnings conference call or presentation 2-May-19 12:00pm GMT

    Q1 2019 Novocure Ltd Earnings Call

  • 5 Key Takeaways From NovoCure's Big First-Quarter
    Motley Fool2 months ago

    5 Key Takeaways From NovoCure's Big First-Quarter

    Management talks about international expansion, potential FDA approval, and Medicare reimbursement.